Generic Name:
Bendamustine hydrochloride
Project Status:
Complete
Therapeutic Area:
Non-Hodgkin Lymphoma and Mantle Cell Lymphoma
Manufacturer:
Lundbeck Canada Inc.
Brand Name:
Treanda
Project Line:
Reimbursement Review
Project Number:
PC0010-000
NOC Date:
Details
Strength:
25 mg/vial and 100 mg/vial
Tumour Type:
Lymphoma
Indications:
Non-Hodgkin lymphoma (NHL)
Funding Request:
For patients with indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (first line and relapse/refractory)
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Lundbeck Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued: